Piribo Eli Lilly New Publication Announcement



Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called 's8220;Eli Lilly - Prospects to 2010's8221;.

Lilly focuses its research on six core therapeutic areas including neuroscience, cancer and infectious diseases. This report provides a full review of the company'ss activities together with sales forecasts for key products to 2010.

Lilly is headquartered in the US and has approximately 42,000 employees worldwide. It markets its products in 158 countries and has research and development facilities in nine countries.

Current Growth Drivers
Lilly has developed a strong product portfolio with five blockbuster products with sales in excess of US$1 billion. The following products will form the basis of Lilly'ss short term growth:
Zyprexa (olanzapine) is a thienobenzodiazepine antipsychotic with a unique receptor-binding profile indicated for the treatment of schizophrenia and related conditions. In 2005, it remained Lilly'ss top selling product with sales in excess of US$4 billion.
Cymbalta (duloxetine) a selective serotonin and norepinephrine reuptake inhibitor, indicated for depression, stress urinary incontinence and diabetic peripheral neuropathic pain.
Evista (raloxifene) is a selective oestrogen receptor modulator principally indicated for the treatment of postmenopausal osteoporosis.
Humalog (insulin lispro) is a recombinant analogue of human insulin used in the treatment of diabetes.
Gemzar (gemcitabine) is a cytarabine analogue, developed by Lilly for the treatment of non-small cell lung cancer, pancreatic and other types of cancer.
Alimta (pemetrexed disodium) is a multi-targeted antifolate that inhibits several enzymes in the biochemical pathways of folate metabolism, which disturb a cancer cell'ss machinery and prevent it from multiplying.
Key Late-Phase Products Reaching the Market Place
Byetta (exenatide) is the first in a new class of drugs for the treatment of Type II diabetes called incretin mimetics and exhibits many of the same effects as the human incretin hormone, glucagon-like peptide-1. It was launched in the US in June 2005.

Pharmaceutical company intelligence reports provide a full review of the company'ss activities together with five-year sales forecasts for its key products. The company'ss financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company'ss product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Contents
Executive Summary
Product Portfolio / Research & Development
Appendix 1 - Financial Performance
Appendix 2 - Key Agreements
Appendix 3 - Infrast Ructure
Appendix 4 - Key Pharmaceutical
Subsidiaries / Joint Vent Ures

's8220;Eli Lilly - Prospects to 2010's8221; is available from Piribo. For more information go to: http://www.piribo.com/publications/pharmaceutical_companies/eli_lilly/eli_lilly_prospects_2010.html

Piribo Product ID: ESP960

About Piribo:
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK's8217;s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.





Piribo Eli Lilly New Publication Announcement